FACTS
An experimental Alzheimer’s pill called AR1001 slowed the disease by 31% over one year in patients who took it without other Alzheimer’s medicines, its maker AriBio said on Monday, Nov. 16. But across everyone in the Phase 3 trial, the difference from a placebo was too small to count as a real effect, according to the company’s announcement. The drug is not approved anywhere.
How AR1001 works
AR1001 is a once-daily pill. It belongs to a class of drugs called PDE5 inhibitors, which works in a way similar to Viagra, Clinical Trials Arena reported. Rather than clearing protein plaques from the brain, as the approved drugs Leqembi and Kisunla do, it relaxes blood vessels to improve blood flow to the brain.
What the AR1001 trial found
The trial, called POLARIS-AD, enrolled 1,535 people at about 230 sites in 13 countries and ran for 52 weeks. Results were presented at the Clinical Trials in Alzheimer’s Disease conference.
Researchers measured decline with a standard memory and thinking scale called CDR-SB.
- Patients taking AR1001 alone (604 people): decline was 0.44 points smaller than with a placebo, a 31% slowing. The result was statistically significant.
- All patients: the difference was 0.11 points, which was not statistically significant.
The weaker overall result suggests the drug may help less when combined with other Alzheimer’s symptom treatments, Clinical Trials Arena reported.
Safety
More patients stopped taking AR1001 because of side effects, 5.2%, than stopped taking the placebo, 1.7%. Four people on the drug died from adverse events, compared with two on the placebo. Diarrhea was reported in 7.7% of people on AR1001 and 4.4% on the placebo. Most side effects were mild to moderate.
What researchers say
AriBio CEO Jai-Jun Choung said, “The 31% slowing of clinical decline at one year in the Monotherapy population supports our hypothesis.”
Dr. Sharon Sha of Stanford, the trial’s global lead investigator, called the results “encouraging” and said they “warrant further evaluation alongside the overall population outcome.”
Richard Oakley of the Alzheimer’s Society, a British charity that was not involved in the trial, called the results an “exciting sign.” He added that the drug “doesn’t seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needs further investigation.”
What comes next
AriBio, a South Korean company, said it will share the full results with the U.S. Food and Drug Administration to decide next steps. An open-label extension of the trial, where all participants can take the drug, runs through the third quarter of 2027.
Anyone with questions about Alzheimer’s treatment should talk with their doctor. See more health news.






